AbCellera Biologics Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.36%.
Did ABCL Beat Earnings? Q2 2025 Results
AbCellera Biologics delivered a standout second quarter, posting revenue of $17.08 million, a 133.3% year-over-year jump that cleared the $6.24 million consensus estimate by 173.69%, while its loss per share of $0.12 came in well ahead of the $0.16 analysts had expected, representing a 25.00% beat. The primary engine behind the revenue acceleration was a dramatic expansion in licensing revenue, which climbed to $10.45 million from just $370,000 a year ago, signaling that partner programs are beginning to generate meaningful downstream returns. Net loss narrowed modestly to $34.73 million as total operating expenses fell to $66.67 million from $100.78 million, aided in part by sharply lower depreciation and impairment charges. Beyond the financials, the quarter marked a genuine operational shift, with AbCellera initiating dosing in a Phase 1 trial of ABCL635 for vasomotor symptoms and launching a second trial for ABCL575 in atopic dermatitis. The company enters the back half of 2025 with roughly $753 million in total available liquidity, and expects initial clinical data from ABCL635 in mid-2026.
- Licensing revenue increased significantly to $10.4 million from $0.4 million in Q2 2024
- Research fees grew to $6.6 million from $5.5 million year-over-year
- R&D expenses decreased to $39.2 million from $40.9 million reflecting ongoing optimization
- G&A expenses declined to $19.0 million from $20.2 million
- Depreciation, amortization, and impairment charges dropped significantly to $5.5 million from $36.5 million
“In the second quarter we hit two critical milestones, receiving authorization to initiate Phase 1 studies for both ABCL635 and ABCL575. I am pleased to announce today that we have successfully begun dosing the first participants in the Phase 1 study of ABCL635. This is a landmark achievement for AbCellera, one that completes our transition to a clinical-stage biotechnology company.”
AbCellera Biologics CEO, on the earnings call
Forward Guidance & Outlook
AbCellera expects initial safety and efficacy data from the Phase 1 study of ABCL635 to be presented in mid-2026. The company has completed its platform investments in the first half of 2025 and has initiated activities at a new clinical manufacturing facility. With approximately $753 million in total available liquidity (including ~$580 million in cash, equivalents, and marketable securities plus ~$173 million in non-dilutive government funding), the company states it is well-positioned to execute on its strategy of advancing its internal pipeline and maintaining partner programs.
ABCL YoY Financials
ABCL Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.